AstraZeneca Pharma India Limited (ASTRAZEN.BO)
INR 6485.35
(0.07%)
INR 6485.35
(0.07%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 599.55 Million | 582.9 Million | 1 Billion | 1.04 Billion | 874.2 Million | 549.8 Million |
| Net Income | 1.61 Billion | 1.34 Billion | 830.4 Million | 1.27 Billion | 1.13 Billion | 726.7 Million |
| Depreciation & Amortization | 149.4 Million | 162.6 Million | 169.5 Million | 197.5 Million | 185.8 Million | 149.2 Million |
| Deferred income taxes | - | -417.6 Million | -233.7 Million | -317.5 Million | -325 Million | -319.2 Million |
| Stock-based compensation | 27.38 Million | 23.71 Million | 18.2 Million | 14.8 Million | 11.2 Million | 9.5 Million |
| Change in working capital | -1.28 Billion | -301.9 Million | 328.9 Million | -39.5 Million | -26.6 Million | 98.1 Million |
| Other non-cash items | 1.61 Billion | -224.9 Million | -105.3 Million | -78.4 Million | -110.9 Million | -114.5 Million |
| Investing Cash Flow | -103.51 Million | 181.1 Million | 47.4 Million | 1.73 Billion | -1.7 Billion | 42.8 Million |
| Investments in PPE | -107.64 Million | -85.2 Million | -96.2 Million | -77.1 Million | -142.2 Million | -186.9 Million |
| Acquisitions | 4.13 Million | 34.8 Million | 32.5 Million | 24.2 Million | 4.9 Million | 2.7 Million |
| Investment purchases | - | - | - | - | -1.69 Billion | -330 Million |
| Sales/Maturities of investments | - | - | - | 1.69 Billion | - | 446.8 Million |
| Other Investing Activities | 325 Million | 231.5 Million | 111.1 Million | 93.2 Million | 119.3 Million | 110.2 Million |
| Financing Cash Flow | -443.72 Million | -244.8 Million | -94.6 Million | -89.7 Million | -63.6 Million | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | -400 Million | -200 Million | -50 Million | -50 Million | -30.1 Million | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -43.8 Million | -44.8 Million | -44.6 Million | -39.7 Million | -38.6 Million | - |
| Accounts receivables | -506.23 Million | -236.3 Million | -47.1 Million | -45.7 Million | -58.6 Million | -281.3 Million |
| Accounts payables | -313.66 Million | 374.4 Million | 96.7 Million | -313.4 Million | 414.5 Million | 552.7 Million |
| Inventory | -376.67 Million | -499.9 Million | 195.8 Million | 53.5 Million | -470.3 Million | -49.6 Million |
| Other working capital | -85.08 Million | 59.9 Million | 83.5 Million | 266.1 Million | 87.8 Million | -123.7 Million |
| Cash at beginning of period | 5 Billion | 4.48 Billion | 3.52 Billion | 835 Million | 1.73 Billion | 1.13 Billion |
| Cash at end of period | 5.05 Billion | 5 Billion | 4.48 Billion | 3.52 Billion | 835 Million | 1.73 Billion |
| Capital Expenditure | -107.64 Million | -85.2 Million | -96.2 Million | -77.1 Million | -142.2 Million | -186.9 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 53.62 Million | 519.2 Million | 960.8 Million | 2.68 Billion | -897.4 Million | 592.6 Million |
| Free Cash Flow | 491.91 Million | 497.7 Million | 911.8 Million | 970.7 Million | 732 Million | 362.9 Million |
| Breakdown | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 1.61 Billion | 158 Million | 523.69 Million | 538.6 Million | 1.34 Billion | 293.04 Million |
| Depreciation & Amortization | 149.4 Million | 37.04 Million | 36.73 Million | 37.97 Million | 162.6 Million | 41.32 Million |
| Deferred income taxes | - | - | - | - | -417.6 Million | - |
| Stock-based compensation | 27.38 Million | - | - | - | 23.71 Million | - |
| Change in working capital | -1.28 Billion | - | - | - | -301.9 Million | - |
| Other non-cash items | 1.61 Billion | -37.04 Million | -36.73 Million | -37.97 Million | -224.9 Million | -41.32 Million |
| Investing Cash Flow | -103.51 Million | - | - | - | 181.1 Million | - |
| Investments in PPE | -107.64 Million | - | - | - | -85.2 Million | - |
| Acquisitions | 4.13 Million | - | - | - | 34.8 Million | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | 231.5 Million | - |
| Financing Cash Flow | -443.72 Million | - | - | - | -244.8 Million | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | -400 Million | - | - | - | -200 Million | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | -44.8 Million | - |
| Accounts receivables | -506.23 Million | - | - | - | -236.3 Million | - |
| Accounts payables | -313.66 Million | - | - | - | 374.4 Million | - |
| Inventory | -376.67 Million | - | - | - | -499.9 Million | - |
| Other working capital | -85.08 Million | - | - | - | 59.9 Million | - |
| Cash at beginning of period | 5 Billion | 5.2 Billion | 4.67 Billion | - | 4.48 Billion | 4.69 Billion |
| Cash at end of period | 5.05 Billion | 158 Million | 5.2 Billion | 538.6 Million | 5 Billion | 293.04 Million |
| Capital Expenditure | -107.64 Million | - | - | - | -85.2 Million | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 53.62 Million | -5.04 Billion | 523.69 Million | 538.6 Million | 519.2 Million | -4.4 Billion |
| Free Cash Flow | 491.91 Million | 158 Million | 523.69 Million | 538.6 Million | 497.7 Million | 293.04 Million |
PANG
ATH-PA
603055
002673
HRMNYCP
3221